Yuku free message boards

Laryngoscope. 2011 Apr;121(4):888-93. doi: 10.1002/lary.21461.
Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study.
Sziklai I, Szilvássy J, Szilvássy Z.
Source
Department of Oto-Rhino-Laryngology and Head and Neck Surgery, University of Debrecen, Debrecen, Hungary. isziklai@dote.hu


Abstract
OBJECTIVES/HYPOTHESIS:
Since the concept of tinnitus dopaminergic pathway emerged, studies have been proposed to investigate if dopaminergic agents influence tinnitus. We hypothesized that pramipexole, an agonist on D2/D3 receptors, may antagonize tinnitus in the presbycusis patients (in the frequency range of 250 to 8,000 Hz) in a dose schedule accepted for the treatment of Parkinson's disease in elderly people.

STUDY DESIGN:

We designed a randomized, prospective, placebo-controlled and double-blind trial.

METHODS:

Forty presbycusis patients aged 50 years or older with subjective tinnitus were randomized to two groups (20 patients in both). Patients in the drug group took pramipexole over a period of 4 weeks according to a treatment schedule as follows: week 1, 0.088 mg t.i.d.; week 2, 0.18 mg t.i.d.; week 3, 0.7 mg t.i.d.; week 4, 0.18 mg t.i.d. over 3 days and 0.088 mg t.i.d. the rest of the week. Patients in the second group received placebo. Determination of subjective grading of tinnitus perception, the tinnitus handicap inventory (THI) questionnaire and electrocochleography (ECOG) examinations served as the end points. Subjective audiometry was used to produce secondary data. A significant improvement in tinnitus annoyance is found in the group treated with pramipexole versus placebo with respect to inhibition of tinnitus and a decrease of tinnitus loudness greater than 30 dB. However, neither ECOG nor subjective pure-tone threshold audiometry revealed any change in hearing threshold in response to either pramipexole or placebo.

CONCLUSIONS:

Pramipexole is an effective agent against subjective tinnitus associated with presbycusis at a dose schedule used for the treatment of Parkinson's disease. The drug did not change hearing threshold.



Interesting. Presbycusis is age-related hearing loss. This study enrolled older people with hearing loss and tinnitus. Tinnitus was reduced but hearing loss remained. Why HINK had weight loss and increased libido is unexplained. Pramipexole doesn't seem to have much to do with those body systems. Might be a secondary effect from sleeping better. gl